Business Context and Reporting Period
This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc.) on October 19, 2017. The filing details the results of the Company's Annual Meeting of Stockholders held on that date and the subsequent approval of amendments to its equity incentive plans.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and equity plan administration.
Material Changes and Corporate Actions
- Stock Incentive Plan Amendment: Stockholders approved an amendment to the 2013 Stock Incentive Plan, increasing the number of shares available for issuance by 1,000,000. The total shares available under the amended plan are now 3,000,000. As of October 19, 2017, 1,956,849 shares of the original 2,000,000 had already been issued.
- Executive Equity Grants: The Board of Directors approved grants of Restricted Stock Units (RSUs) and stock options to key executives, including CEO Molly Hemmeter, CFO Gregory Skinner, COO Ronald Midyett, and VP Steven Bitler. RSUs vest on the third anniversary, while options vest monthly over 36 months.
- Director Elections: Five Class 2 directors were elected with significant majority support, though broker non-votes were substantial (2,529,889 shares for each nominee).
- Accounting Firm Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending May 27, 2018.
- Executive Compensation Vote: Stockholders approved a non-binding advisory vote on executive compensation and indicated a preference for holding such votes annually.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies are disclosed in this report other than the standard governance procedures outlined.
Investor Verification Checklist
- Verify the total number of shares authorized under the amended 2013 Stock Incentive Plan (3,000,000) and the remaining unissued shares.
- Review the specific vesting schedules and grant terms for the RSUs and options awarded to named executive officers.
- Confirm the fiscal year end date referenced in the auditor ratification (May 27, 2018).
- Note the high volume of broker non-votes in the director elections, which may indicate significant institutional holdings without voting instructions.